(Total Views: 262)
Posted On: 03/09/2017 11:39:08 AM
Post# of 106808
Bot back in $INNV $0.2045
after selling into candle .26
Big move still to come with (delayed so far)
FDA approval of over the counter Fluticare.
As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. Would strongly challenge Flonase, current OTC #1.
The stock is priced as if there will not be an FDA approval.
after selling into candle .26
Big move still to come with (delayed so far)
FDA approval of over the counter Fluticare.
As the #1 prescription nasal steroid with over 177 million units sold since 2007, Innovus believes that the over-the-counter version of FlutiCare™ could be worth up to $1 billion per year by addressing a much wider over-the-counter market. Would strongly challenge Flonase, current OTC #1.
The stock is priced as if there will not be an FDA approval.
(0)
(0)
